Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

被引：28
|
作者：
Schmid, P. [1 ]
Jung, K. H. [2 ]
Wysocki, P. J. [3 ]
Jassem, J. [4 ]
Ma, C. X. [5 ]
Fernandes, R. [6 ]
Huisden, R. [7 ]
Stewart, R. [8 ]
Vukovic, P. [9 ]
Nunes, A. Tablante [10 ]
Nowecki, Z. [11 ]
机构：
[1] Queen Mary Univ London, Ctr Expt Canc Med, Barts Canc Inst, London, England
[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[3] Jagiellonian Univ Med Coll, Dept Oncol, Krakow, Poland
[4] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
[5] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
[6] Western Univ, London Hlth Sci Ctr, Div Med Oncol, Dept Oncol,Schulich Sch Med & Dent, London, ON, Canada
[7] AstraZeneca, Stat, Cambridge, England
[8] AstraZeneca, Translat Med, Oncol, Cambridge, England
[9] AstraZeneca, Late Dev Oncol, Cambridge, England
[10] AstraZeneca, Global Med Dev, Gaithersburg, MD USA
[11] Maria Sklodowska Curie Natl Res Inst Oncol, Breast Surg, Warsaw, Poland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.185
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166MO
引用
收藏
页码：S199 / S199
页数：1
相关论文
共 50 条
  • [21] ASCENT-03: Phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
    Bardia, A.
    Punie, K.
    Barrios, C. H.
    Schneeweiss, A.
    Zhai, X.
    Huynh, D. H.
    Vaksman, N.
    Lai, C.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S663 - S664
  • [22] ASCENT-03: Phase 3 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in first-line (1L) metastatic triple-negative breast cancer (mTNBC)
    Huober, J.
    Bardia, A.
    Punie, K.
    Barrios, C.
    Schneeweiss, A.
    Zhai, S.
    Huynh, D.
    Vaksman, N.
    Lai, C.
    Tolaney, S. M.
    SWISS MEDICAL WEEKLY, 2022, 152 : 44S - 45S
  • [23] Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
    Schmid, Peter
    Loirat, Delphine
    Savas, Peter
    Espinosa, Enrique
    Boni, Valentina
    Italiano, Antoine
    White, Shane
    Singel, Stina M.
    Withana, Nimali
    Mani, Aruna
    Li, Suwen
    Harris, Adam
    Wongchenko, Matthew
    Sablin, Marie
    CANCER RESEARCH, 2019, 79 (13)
  • [24] First-line (1L) fuzuloparib plus mfolfirinox followed by maintenance fuzuloparib in patients (pts) with unresectable locally advanced or metastatic (LA/M) pancreatic cancer (PC): A phase Ib study
    Yu, X.
    Mou, Y.
    Chen, X.
    Liu, C.
    Zhang, X.
    Xu, J.
    Zhang, J.
    Shi, S.
    Wei, M.
    Li, J.
    Liu, R.
    Gao, S.
    Xu, L.
    Sheng, Z.
    Lian, J.
    Shi, Q.
    ANNALS OF ONCOLOGY, 2023, 34 : S901 - S902
  • [25] TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-breast cancer
    Mcarthur, Heather L.
    Tolaney, Sara M.
    Dent, Rebecca
    Schmid, Peter
    Asselah, Jamil
    Liu, Qiang
    Meisel, Jane Lowe
    Niikura, Naoki
    Park, Yeon Hee
    Werutsky, Gustavo
    Bianchini, Giampaolo
    Andersen, Jay C.
    Kozarski, Robert
    Rokutanda, Nana
    Pistilli, Barbara
    Loibl, Sibylle
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [26] TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression
    Okamoto, I.
    Kuyama, S.
    Girard, N.
    Lu, S.
    Franke, F. A.
    Pan, E.
    Ren, N.
    Chen, A.
    Oputa, E.
    Lisberg, A. E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [27] Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.
    Sun, Yuping
    Xiao, Zuke
    Cheng, Ying
    Li, Juan
    Tu, Hai Yan
    Long, Jianlin
    Lin, Xiaoyan
    Li, Wei
    Zhao, Jun
    Wang, Yan
    Chen, Yuan
    Ma, Rui
    Liu, Yinglei
    Lu, Min
    Zhang, Biao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Phase I results of the phase I/II study of pembrolizumab in combination with binimetinib in patients with unresectable locally advanced or metastatic triple-negative breast cancer
    Chumsri, Saranya
    Polley, Mei-Yin
    Mathur, Pulkit
    Reis, Aline
    Tenner, Kathleen S.
    Weidner, Morgan
    Advani, Pooja
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    Knutson, Keith L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [29] Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial
    Schmid, P.
    McArthur, H. L.
    Cortes, J.
    Xu, B.
    Cardoso, F.
    Casalnuovo, M. L.
    Demirci, U.
    Freitas, R., Jr.
    Ghosh, J.
    Hegg, R.
    Iwata, H.
    Chuken, Y. A. Lopez
    Nechaeva, M.
    Robson, M. E.
    Villalobos Valencia, R.
    Lloyd, A.
    D'Cruz, C.
    Foxley, A.
    Park, Y. H.
    ANNALS OF ONCOLOGY, 2024, 35 : 1212 - 1213
  • [30] SGNLVA-002: Single arm, open label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer
    Boni, V.
    Alemany, C.
    Meisel, J. L.
    Sinha, R.
    Sterrenberg, D.
    Tkaczuk, K. H. R.
    Wang, Y.
    Wang, Z.
    Han, H. S.
    ANNALS OF ONCOLOGY, 2019, 30
12345